YILI(SH:600887) Xin Hua Cai Jing·2026-02-11 08:37Core Insights - YLGB-1496, a probiotic strain developed by Yili, has been included in the list of probiotics approved for infant food by the National Health Commission of China, marking a significant breakthrough in the domestic probiotic industry [1][3] Group 1: Probiotic Development - YLGB-1496 is the first probiotic strain in the list that is independently developed by a Chinese dairy company and derived from healthy human breast milk [1][3] - The strain is designed to be more compatible with the physical needs of Chinese infants, providing a tailored probiotic solution [1][3] Group 2: Scientific Validation - Clinical studies conducted in collaboration with the National Dairy Technology Innovation Center have shown that YLGB-1496 significantly reduces the incidence of eczema and respiratory infections in infants, aiding in the development of their immune systems [3] - The strain has also been proven to enhance gut comfort in infants, reducing the occurrence and severity of diarrhea symptoms [3] Group 3: Commercialization and Future Plans - Yili's subsidiary, Jinqi Biotechnology, is responsible for the industrial production and commercialization of YLGB-1496, supporting the upgrade of the health food industry towards high quality and diversification [4] - The strain has already been incorporated into several products, including QQ Star's maternal care products and mixed fruit and vegetable juices, with plans for broader application in infant formula [4] - The approval of YLGB-1496 signifies a major leap for China's dairy industry from technology following to independent innovation in the probiotic sector [4]